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To examine the resistance rates and epidemiology of Streptococcus pneumoniae in Brooklyn, New York,
isolates were collected during two boroughwide surveillance periods in 1997 and 1999. Of 138 isolates,
67% were susceptible to penicillin and 34% to ciprofloxacin. Susceptibility rates to ciprofloxacin decreased
dramatically from 1997 to 1999 (47% to 16%, p=0.0003). Five isolates (3.6%) were resistant to levofloxa-
cin. Western Brooklyn had lower rates of susceptibility to penicillin compared with eastern neighborhoods.
More isolates in the eastern neighborhoods belonged to the Spanish/French 9/14 clone, and isolates in the
western neighborhoods tended to belong to the Spanish/USA 23F clone. Residents of the western neigh-
borhoods were more likely to be white and elderly and less likely to be receiving Medicaid or public assis-
tance, characteristics associated with increased health-care and antibiotic use. Brooklyn residents appear
to be at high risk for fluoroquinolone-resistant S. pneumoniae. Our results underscore the need for vigilant
regional surveillance. 
treptococcus pneumoniae with reduced susceptibility to
penicillin has become common in many areas, including
Europe (1–3) and North America (4–8). In 1995, 20% of
bloodstream isolates in New York City were nonsusceptible to
penicillin (9), as were 29% from the northeast United States
from 1996 to 1997 (6). In a national survey from 1995 to 1998
involving >4,000 isolates, 24% were resistant to penicillin
(10). The Southeast has recorded the highest resistance rates
(approximately one third of isolates) (10). Pneumococcal iso-
lates from nonsterile sites (1,3,9) and from children (3,5,8)
tend to be more resistant. In addition, recent receipt of antibi-
otics has been consistently recognized as a risk factor for hav-
ing resistant S. pneumoniae (3,11–15). Many isolates resistant
to penicillin are also resistant to other antimicrobial drugs
(1,8,16), and therapeutic options have become quite limited. In
this report, we describe the resistance rates and epidemiology
of S. pneumoniae in the borough of Brooklyn, New York.
Methods
Isolates of S. pneumoniae were collected during two bor-
oughwide surveillance efforts conducted in 1997 and 1999.
Consecutive single patient isolates were collected from the
microbiology laboratories of 16 major hospitals in Brooklyn.
Serotypes were determined by a quellung reaction. All suscep-
tibility tests were performed in the research laboratory of the
investigators. Isolates collected in 1997 underwent susceptibil-
ity testing by the broth microdilution technique with Mueller-
Hinton broth containing 4% lysed horse blood, according to
the National Committee for Clinical Laboratory Standards
(NCCLS) methods (17). Fluoroquinolone MICs of the 1997
isolates were confirmed by E-test, as were all susceptibility
tests performed with the 1999 isolates. Susceptibility break-
points were defined according to NCCLS standards (17) or the
manufacturer’s recommendations. An isolate was considered
resistant if it had either intermediate or high-level resistance to
an antibiotic.
Iolates of S. pneumoniae were fingerprinted with contour-
clamp homogeneous electric-field (CHEF) electrophoresis,
according to established methods (18). Genomic DNA in agar-
ose plugs was digested with Sma1 and placed into 1% agarose
gel. Electrophoresis was performed on a CHEF DR II appara-
tus (Bio-Rad Laboratories, Hercules, CA) with a pulse time of
2 to 30 seconds for 22 hours at 14°C. The gel was then stained
with ethidium bromide. Strains were considered identical if
they shared every band, closely related if they differed by one
to three bands, possibly related if they differed by four to six
bands, and unrelated if they differed by seven or more bands
(19). Isolates were compared with previously identified clones
collected from North America (20).
1990 census data were used to determine boundaries and
demographic information for the Brooklyn neighborhoods
(21). Categorical data were compared by using chi-square
analysis or Fisher’s exact test. This study was approved by the
Institutional Review Board at the State University of New
York Downstate Medical Center.
Results
One hundred thirty-eight isolates of S. pneumoniae were
collected, 81 from 1997 and 57 from 1999. For the isolates for
which clinical data were available, 56% were isolated from
blood cultures and 41% from respiratory tract cultures; 68%
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were from adults and 32% from children. Overall, the percent-
age of isolates susceptible to penicillin was 67% (Table) and
was similar for the two collection periods. Four isolates (3%)
had penicillin MICs of 4 µg/mL. Resistance to erythromycin
was detected in 25%. All the isolates were susceptible to van-
comycin, quinupristin-dalfopristin, and linezolid; 34% were
susceptible to ciprofloxacin, and 23% had MICs of >4 µg/mL.
The ciprofloxacin-susceptibility rate decreased sharply from
1997 to 1999 (47% to 16%, p=0.003). Five isolates (3.6%)
were resistant to levofloxacin. Two of these five isolates were
also highly resistant to gatifloxacin and moxifloxacin. All but
one of the penicillin-resistant isolates belonged to serotypes
present in the seven-valent conjugate vaccine (9V 11%; 14
11%; 19F 36%; 23F 21%; and 6B 18%).
Fifty-two isolates were characterized by pulsed-field gel
electrophoresis (PFGE), including 35 isolates resistant to peni-
cillin. Twenty-one clones were recognized, including the
Spanish/USA 23F clone (8 isolates) and the Spanish/French 9/
14 clone (11 isolates). All but one of the Spanish/USA 23F
clones were resistant to erythromycin, compared with only
two isolates of the Spanish/French 9/14 clone. Two other
clones previously recognized in North America (20) were also
recovered; they contained eight and four penicillin-resistant
isolates, respectively. The remaining 21 isolates, largely peni-
cillin-susceptible, belonged to 17 clones consisting of 1 or 2
isolates.
Isolates that were nonsusceptible to ciprofloxacin were
distributed among the different PFGE types. Of 39 isolates
examined, 4 belonged to the Spanish/USA 23F clone, 11 to the
Spanish/French 9/14 clone, and 6 to another clone. The
remaining 18 isolates belonged to smaller clones or were
unique isolates; 11 of these isolates were susceptible to peni-
cillin. Of the levofloxacin-resistant isolates, one belonged to
the Spanish/USA 23F clone, one to the Spanish/French 9/14,
and two to a third clone; one isolate was not studied. All these
isolates were penicillin resistant. 
The penicillin-susceptibility rates in Brooklyn neighbor-
hoods were also examined. The four western neighborhoods
had lower rates of susceptibility to penicillin than the eastern
neighborhoods (57% versus 75%, p=0.046). Significantly
more penicillin-resistant isolates in the eastern neighborhoods
belonged to the Spanish/French 9/14 clone (42% versus 7%,
p=0.047), and more isolates in the western neighborhoods
belonged  to the Spanish/USA 23F clone (27% versus 5%,
p=0.14). Compared with Brooklyn’s east side, the population
in the four western neighborhoods was more likely to be white
(70% versus 36.8%, p<0.001) and elderly (14.3% versus
11.7%, p<0.001) and less likely to be receiving Medicaid
(20.8% versus 28.5%, p<0.001) or public assistance (11.8%
versus 18.3%, p<0.001).
Conclusion
Our results underscore the need for regional (or even
neighborhood) surveillance of community pathogens. Brook-
lyn’s boroughwide rate of penicillin-susceptible S. pneumo-
niae (67%) is comparable with reports in the United States,
including the Northeast (6,10,22). However, in Brooklyn’s
western neighborhoods, just over half of isolates were suscep-
tible to penicillin. A disconcerting rate of reduced susceptibil-
ity to fluoroquinolones was also noted. We found a marked
decrease in the susceptibility rates for ciprofloxacin over a rel-
atively short time period (from 47% in 1997 to 16% in 1999);
3.6% of all isolates were resistant to levofloxacin. Although
susceptibility rates of 50% to 75% have been reported for
ciprofloxacin (22,23), isolates frankly resistant (MIC >4 µg/
mL) to ciprofloxacin or resistant to newer fluoroquinolones
have been uncommon. Less than 10% of Canadian and U. S.
isolates are reportedly resistant to ciprofloxacin (22–24), com-
pared with 23% in our study. Levofloxacin resistance was
found in 7 of 4,013 isolates collected nationally (10); we
recovered 5 levofloxacin-resistant strains from our collection
of 138 isolates. 
Brooklyn is apparently at particular risk for the emergence
of highly fluoroquinolone-resistant S. pneumoniae. Because
few of our isolates were highly resistant to penicillin (MICs >4
µg/mL), β -lactam antibiotics remain a preferred option (11)
Table. Antibiotic susceptibility rates of 138 Streptococcus pneumoniae isolates
Antibiotic MIC50 (µg/mL) MIC90 (µg/mL) Range (mg/mL) Susceptible (%) Intermediate (%) Resistant (%)
Penicillin 0.03 2 0.008-4.0 67 16 17
Ceftriaxone 0.015 1 0.004-2.0 87 11 2
Cefepime 0.06 1 0.03-4.0 81 12 7
Meropenem 0.015 0.5 0.004-2.0 82 14 4
Erythromycin 0.125 8 ≤ 0.015->256.0 75 2 23
Clindamycin 0.125 0.5 0.03->256.0 93 1 6
Ciprofloxacin 2 4 0.5->32.0 34 43 23
Levofloxacin 1 2 0.5->8.0 96.4 2.2 1.4
Chloramphenicol 4 4 ≤  0.5-64.0 90 10
Linezolid 0.5 1 ≤  0.125-2.0 100
Quinupristindalfopristin 0.5 0.5 0.125-1.0 100RESEARCH
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for treating community-acquired pneumonia in the area.
Clearly, local surveillance is essential to aid clinicians in mak-
ing therapeutic decisions.
The epidemiology of resistant community pathogens can
be complex and related to several factors, including prior anti-
biotic exposure (3,12–15) and access to health care. Our
results are in agreement with others (5,16) in showing that cer-
tain demographic groups are at higher risk of acquiring resis-
tant bacteria, possibly secondary to increased antibiotic use
(13,15,25). The population of Brooklyn’s west side, which has
the demographic characteristics of a population that uses high
amounts of antibiotics, had penicillin-resistance rates that
reached 50%. Our molecular epidemiology  studies showed
that the Spanish/USA 23F clone, along with two other North
American clones, predominated in the western half of the bor-
ough. The Spanish/USA 23F clone is to known to be more
resistant to other classes of antibiotics, including macrolides
(20). In contrast, the Spanish/French 9/14 clone predominated
in the east side. Most of these strains remain susceptible to
macrolides (20), as were the isolates in our study. 
Strategies to limit the spread of resistant S. pneumoniae
include improved surveillance, reduced antibiotic usage, and
greater vaccination of persons at high risk (5,16,26–28). Edu-
cational efforts aimed at both health-care providers and those
at higher risk are needed to reduce inappropriate antibiotic
usage. Aggressive surveillance measures are especially needed
in Brooklyn to monitor the emergence of highly fluoroqui-
nolone-resistant S. pneumoniae.
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